• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Nutraceuticals
    • Markets
    • Health
    • Jobs
    • Events
    • Buyers' Guide
    • Showcases
    • More
  • Magazine
  • News
  • Exclusives
  • Nutraceuticals
  • Markets
  • Health
  • Jobs
  • Events
  • Buyers' Guide
  • Showcases
  • Current & Past Issues
    Features
    Columns
    Editorials
    Digital Edition
    Subscribe Now
    Advertise Now
    eNewsletter
    Editorial Guidelines
    Top Features
    A Kingdom of Their Own: Fungi Shine While Mushrooms Emerge as Market Stars

    The Pet Health Boom: Supplement Growth Set to Build on Rapid Expansion

    (Re)Open for Business: China’s Strong Demand for Natural Products Spells Opportunity for U.S. Brands

    Review Finds No Causative Connection Between Dietary Supplements and Eating Disorders

    KA! Empathogenics: Creating Calm and Connectedness with Inspiration from Nature
    Breaking News
    Certifications, Approvals and Patents
    Exclusives
    Industry & Market News
    People
    Products
    Regulatory
    Glossary
    Research
    Supplier News
    Supplier Insights
    Live From Shows
    Top News
    Verdure Sciences Receives Award for Sustainable, Ethical Turmeric Sourcing

    BGG Receives Patent for Saw Palmetto ID Method

    Premium Label & Packaging Solutions Receives Safe Quality Food (SQF) Certification

    Inulinase Enzymes May Benefit Gut Symptoms of FODMAP Digestion

    Verdure Sciences’ Boswellia Ingredient Receives USP Verification
    Exclusives
    Blogs & Guest Articles
    Health E-Insights
    Area Code 420
    eBook
    Antioxidants
    Dairy-Based Ingredients
    Enzymes
    Fatty Acids
    Fiber & Carbohydrates
    Green Foods
    Herbs & Botanicals
    Marine Nutraceuticals
    Minerals
    Omega 3s
    Probiotics & Prebiotics
    Proteins, Peptides, Amino Acids
    Sweeteners
    Vitamins

    A Kingdom of Their Own: Fungi Shine While Mushrooms Emerge as Market Stars

    Verdure Sciences Receives Award for Sustainable, Ethical Turmeric Sourcing

    BGG Receives Patent for Saw Palmetto ID Method

    ‘Uniquely Unbound’: Releasing the Potential, and Genius, of Walnuts

    Inulinase Enzymes May Benefit Gut Symptoms of FODMAP Digestion
    Consumer Trends
    Contract Manufacturing
    Cosmeceuticals / Nutricosmetics
    Delivery & Dosage Technologies
    Dietary Supplements
    Flavors & Colors
    Functional Foods & Beverages
    Healthcare Trends
    Medical Nutrition
    Mergers & Acquisitions
    Natural/Organic
    Nutrition Bars
    Packaging
    Pet Nutraceuticals
    Quality & Safety
    Regulations
    Research
    Testing
    World Markets

    A Kingdom of Their Own: Fungi Shine While Mushrooms Emerge as Market Stars

    Verdure Sciences Receives Award for Sustainable, Ethical Turmeric Sourcing

    BGG Receives Patent for Saw Palmetto ID Method

    The Pet Health Boom: Supplement Growth Set to Build on Rapid Expansion

    ‘Uniquely Unbound’: Releasing the Potential, and Genius, of Walnuts
    Bone & Joint Health
    Cancer Risk
    Cardiovascular Health
    Cognitive Function
    Diabetes & Blood Sugar Management
    Digestive Health
    Energy
    Eye Health
    Healthy Aging
    Immune Function
    Infant & Children's Health
    Inflammation
    Men's Health
    Mood Health & Sleep
    Oral Health
    Sexual & Reproductive Health
    Skin Health
    Sports Nutrition
    Weight Management/Weight Loss
    Women's Health

    A Kingdom of Their Own: Fungi Shine While Mushrooms Emerge as Market Stars

    ‘Uniquely Unbound’: Releasing the Potential, and Genius, of Walnuts

    Inulinase Enzymes May Benefit Gut Symptoms of FODMAP Digestion

    Gaming and Esports Health Concerns

    Bioiberica’s DAOgest Authorized as Novel Food ingredient in EU
    Industry Events
    Live From Show Events
    Webinars
    All Companies
    Categories
    Trade Associations
    Company Capabilities
    International Buyers Guide Companies
    Applied Food Sciences, Inc.

    Bioenergy Life Science, Inc. (BLS)

    Verdure Sciences

    Premium Labels & Packaging Solutions

    PhytoGaia Inc
    Companies
    Product Releases
    News Releases
    Literature / Brochures
    White Papers
    Jobs
    VIdeos
    Services
    Add New Company
    International Buyers Guide Companies
    Applied Food Sciences, Inc.

    Bioenergy Life Science, Inc. (BLS)

    Verdure Sciences

    Premium Labels & Packaging Solutions

    PhytoGaia Inc
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • All Companies
      • Categories
      • Trade Associations
      • Company Capabilities
    • Nutraceuticals
      • Antioxidants
      • Dairy-Based Ingredients
      • Enzymes
      • Fatty Acids
      • Fiber & Carbohydrates
      • Green Foods
      • Herbs & Botanicals
      • Marine Nutraceuticals
      • Minerals
      • Omega 3s
      • Probiotics & Prebiotics
      • Proteins, Peptides, Amino Acids
      • Sweeteners
      • Vitamins
    • Markets
      • Consumer Trends
      • Contract Manufacturing
      • Cosmeceuticals / Nutricosmetics
      • Delivery & Dosage Technologies
      • Dietary Supplements
      • Flavors & Colors
      • Functional Foods & Beverages
      • Healthcare Trends
      • Medical Nutrition
      • Mergers & Acquisitions
      • Natural/Organic
      • Nutrition Bars
      • Packaging
      • Pet Nutraceuticals
      • Quality & Safety
      • Regulations
      • Research
      • Testing
      • World Markets
    • Health
      • Bone & Joint Health
      • Cancer Risk
      • Cardiovascular Health
      • Cognitive Function
      • Diabetes & Blood Sugar Management
      • Digestive Health
      • Energy
      • Eye Health
      • Healthy Aging
      • Immune Function
      • Infant & Children's Health
      • Inflammation
      • Men's Health
      • Mood Health & Sleep
      • Oral Health
      • Sexual & Reproductive Health
      • Skin Health
      • Sports Nutrition
      • Weight Management/Weight Loss
      • Women's Health
    • Online Exclusives
    • Webinars
    • Slideshows
    • Blogs & Guest Articles
    • Health E-Insights
    • Videos
    • Podcasts
    • Infographics
    • eBook
    • Whitepapers
    • Research
      • TrendSense
      • Monograph Center
      • White Papers
      • Research News
    • Jobs
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Supplier Showcases
      • Companies
      • Product Releases
      • News Releases
      • Literature / Brochures
      • White Papers
      • Jobs
      • VIdeos
      • Services
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Blog

    FDA ‘Chills’ Cannabidiol Marketplace

    Agency sent a series of warning letters to companies marketing dietary supplements containing CBD oil on Feb. 9.

    FDA ‘Chills’ Cannabidiol Marketplace
    Government actions have sparked a legal argument about CBD.
    Robert T. Hoban, Esq., Managing Partner, Hoban & Feola, LLC02.22.16
    Cannabidiol (CBD), which is one of many non-psychoactive substances contained in the plant species, Cannabis sativa L, has received a great deal of attention in recent months. CBD has entered the marketplace in many places and in many forms. Is it legal? Is it scheduled?
     
    Many botanical hemp extractors market and sell CBD in all 50 states. The legality and/or the wisdom of these practices are the subject of great debate in the cannabis industry, which encompasses both industrial/botanical hemp and the ganja/marijuana dispensary regulatory systems.
     
    Fundamentally, CBD is not specifically defined under the Federal Controlled Substances Act (CSA); it simply has not been expressly addressed under federal law. However, the DEA has taken the position that CBD is a Schedule I Controlled Substance as defined under the CSA. Without an express provision under the CSA, it is questionable whether the DEA has any sort of authority to take this position.
     
    But more importantly, in the case of Hemp Industries Association v. Drug Enforcement Association, 333 F.3d 1082 (9th Circuit. 2003), the DEA attempted to initiate rules and interpretations concerning certain cannabinoid constituents of marijuana that were not expressly set forth under the CSA or the DEA’s own regulations (at the time). The Ninth Circuit Federal Court of Appeals struck down its efforts, stating that: “[t]he petition requesting that we declare the rule to be invalid and unenforceable is GRANTED.” In short, an agency, such as the DEA, is not permitted to change a legislative rule retroactively through the process of disingenuous interpretation of the rule to mean something other than its original meaning.
     
    Nonetheless, we have seen a deliberate and wide-ranging effort on behalf of the federal government to “chill” the CBD marketplace. Perhaps this is because there is a general lack of understanding (scientific, legal and practical) on behalf of the federal government and its various relevant agencies as to CBD as a general matter. Perhaps the federal government has a real concern for CBD products intended for human consumption.
     
    FDA Action
    In May 2015, the FDA posted an online forum labeled Marijuana: Questions and Answers (this was later updated/amended in July 2015).
     
    Interestingly, this Q&A came at a time when our law firm had been able to secure a large scale national retailer for placement/sales of CBD products nationwide; this put a pause on this effort. Nonetheless, in this forum, the FDA addressed three “questions” that dealt with CBD. Importantly, the FDA addressed the following: Can products that contain cannabidiol be sold as dietary supplements?
     
    In this informal Q&A, the FDA summarily announced that CBD products are excluded from the dietary supplement definition under section 201(ff)(3)(B)(ii) of the FD&C Act, though questions remain whether all of the factors under that section of the FD&C Act have been satisfied to exclude CBD products from the definition of a dietary supplement.
     
    Then on Feb. 9, the FDA sent a number of warning letters to companies with dietary supplement products containing CBD oil. In all of these letters, the FDA took issue with disease claims made by the companies for the products, which is no surprise. However, of more novel interest is that in all but two of these letters, the FDA identified CBD Oil as a non-permissible dietary ingredient due to its previous investigation as a New Drug in one or more New Drug Applications. The FDA has not previously issued warning letters taking issue with CBD Oil as a dietary ingredient, although this is consistent with the FDA’s previous guidance issued as described above.
     
    State Laws
    Furthermore, this is consistent with many individual states, which have acted under their respective laws to prohibit CBD sales and/or enforce against such producers or sellers (e.g., state-based CSA provisions, unique criminal code provisions addressing cannabis constituents, or state-based medical marijuana laws or restrictive CBD-only laws). State law compliance is an issue too-often overlooked by many CBD producers/sellers, as the primary focus tends to be federal law. States have taken concerted measures to interrupt the CBD marketplace.
     
    U.S. Customs and Border Patrol
    Moreover, there has been an increase of activity concerning imported hemp material with the U.S. Customs and Border Patrol (CBP). We dealt with a spike in hemp import seizures beginning in August 2015, which has led to a number of administrative actions related thereto. Many of these seizures by the CBP were unannounced and, interestingly, no records of the confiscation could be found. These seizures mostly resulted in returning the product to its international sender and/or a finger-pointing scenario where CBP and the private carriers or customs agents would/could provide no information about the shipment’s whereabouts.
     
    Then, the seizures by CBP began to follow a normal, adopted procedure-based pattern of confiscation, where the recipient was notified by the CBP of the seizure. At first, CBP took the position that the import was an illegal dietary supplement and attempted to have the FDA exercise jurisdiction accordingly. But the FDA did not appear to take on this added responsibility and the seized shipments were able to be released.
     
    The strategy appeared to have shifted in the fall of 2015, whereby the CBP would seize the product, test for the presence of THC (without regard to amount), and attempt to have federal law enforcement exercise jurisdiction. Upon information and belief, federal law enforcement did not appear to take a more active role with the CBP.
     
    Thus, without any assistance from other agencies, the CBP acted on its own, and issued its first CBD policy statement in November 2015, which states: “[i]f the product contains tetrahydrocannabinols (THC) and causes THC to enter the human body, it is an illegal substance and may not be imported into the U.S.”
     
    Ironically, this CBP policy cites the DEA’s October 2001 policy related to industrial hemp, which was rendered void by the above-mentioned Hemp Industry Association’s case law. Before this November 2015 transition in policy, CBP’s former position (in practice) was that hemp and/or CBD products containing less than .3% THC were permissible in accordance with relevant case law. CBP has taken this position despite the fact that naturally occurring cannabinoids are not unlawful under the CSA. See: Hemp Industry Association v. DEA, 357 F.3d 1012 (9th Circuit. 2004).
     
    What Does All Of This Mean?
    None of this is surprising. And it should not be taken lightly. In fact, the best conservative practices would dictate a pause in sales and production until the issue is resolved. But the cannabis industry has always proceeded in the face of risk and adversity. That said, what does this mean for the CBD industry?
     
    Let’s start with the FDA. Its analysis as set forth in the Q&A and the Feb. 9 warning letters is incomplete and does not render this issue a “final decision” by the FDA. Instead, the law dictates, pursuant to the FD&C Act, that the conclusion it has reached can be conclusively determined only if substantial clinical investigations have been instituted and for which the existence of such investigations has been made public. No such substantial clinical investigations have been instituted, nor made public to date. Instead, the FDA has summarily announced that these are “substantial clinical investigations.”
     
    But more importantly, the FDA duly notes that, “[t]here is an exception if the substance was ‘marketed as’ a dietary supplement or as a conventional food before the new drug investigations were authorized,” and further invites, “[i]nterested parties [to] present the agency with any evidence that they think has bearing on this issue.”
     
    This begs the question of whether CBD was marketed as a dietary supplement prior to the subject IND application. And it is important to note that following the above-referenced Q&A, the CBD industry provided substantial evidence and information indicating that CBD was, in fact, marketed and sold as a dietary supplement for many years prior to the IND application at issue.
     
    Sarah Syed, director of marketing at CV Sciences, one of the larger CBD companies in the industry stated that, “[i]t is our opinion, which is broadly shared by the marketplace, that CBD has been marketed as a dietary supplement prior to commencement and public notice of any substantial clinical investigations instituted on CBD … thereby rendering the IND preclusion inapplicable.”
     
    Importantly, a number of other dietary supplement ingredients have similarly been subject to the same scrutiny and yet continue to be sold as dietary supplements—red yeast rice, trans-resveratrol, P5P, NAC and DHEA.
     
    Thus, as a practical matter, this announcement by the FDA is premature; is part of a larger discussion; has failed to identify the date of the particular IND (and its applicants); and there is no information to suggest that the IND clinical investigations applicable here preempt the ability to market, sell and produce CBD as a dietary supplement at all. In short, while an important guidance document, the Q&A posting and corresponding position noted in the Feb. 9 warning letters, do not have the effect of a final determination on this issue.
     
    More importantly, the FDA has made no determination or assertion that CBD products are illegal or in any way run afoul of the Controlled Substances Act (CSA). As was established by the Ninth Circuit in 2004, the sale, production and distribution of CBD oils/products derived from imported raw material industrial hemp, such as those produced and sold are not in violation of the CSA (Hemp Industry Association. v. DEA, 357 F.3d 1012 (9th Cir. 2004). In fact, this case stands for the proposition that naturally occurring cannabinoids are not unlawful under the CSA.
     
    Last, under the FDA guidelines, there are a variety of categories in which a product can be placed/registered. This current FDA position addresses the category of “dietary supplements” only. It does not appear that the FDA has taken a position as to the sale or marketing of CBD products as a constituent of hemp, a food product, cosmetic product, other FDA classification, or the like.
     
    Why Is This Happening?
    Fundamentally, this is a very broad attack on the CBD industry. The FDA, FTC, CBP, and the DEA have all contributed to this “chill” in the marketplace. It is surely intentional. But what is the purpose? Is it the stigma associated with “marijuana?” Is it a fundamental lack of understanding concerning the difference between hemp and marijuana? It is probably a combination of these factors.
     
    Regardless of the reason, it would appear that this is a concerted effort to chill the CBD marketplace on all fronts. The perhaps-legitimate confusion and concern expressed by these federal and state agencies about CBD can largely be cured by an act of Congress. And the solution is the Industrial Hemp Farming Act of 2015, which amends the CSA to exclude industrial hemp from the definition of marijuana.
     
    Further, it defines “industrial hemp” to mean the plant Cannabis sativa L. and any part of such plant, whether growing or not, with a delta-nine tetrahydrocannabinol concentration of not more than 0.3% on a dry weight basis.
     
    Maybe these agencies simply want Congress to act? The industry certainly does. And the Industrial Hemp Farming Act of 2015 is the one-size-fits-all answer to many of these questions.
     
    In the meantime, these issues are complex and present a measurable amount of risk. It is strongly advised that you should consult with an attorney prior to marketing or distributing such products to ensure compliance with all applicable laws (including, but not limited to, FDA, FTC, CSA and applicable state laws).



    Robert T. Hoban, Esq., Managing Partner, Hoban & Feola, LLC
    * The information presented is not legal advice, and is not to be acted on as such. It is intended for informational purposes only.
     
    Bob Hoban is Managing Partner with Hoban & Feola, LLC. He is an AV Preeminent rated attorney and seasoned full-service commercial practitioner. He has more than 20 years of diverse legal and practical entrepreneurial business experience. Mr. Hoban is recognized as one of the leading commercial cannabis practitioners nationwide, representing private and publicly-held clients in numerous states and abroad. He has litigated nearly every aspect of Colorado’s Marijuana Code and has closed well-over 200 marijuana-related business transactions. Commercial marijuana and industrial hemp-based business operations, related litigation and regulatory representation are a specialty. Furthermore, Mr. Hoban is devoted to impacting law at its source; he has drafted more than 30 bills for the Colorado General Assembly in policy areas relating to eminent domain, land use, hemp/marijuana and transportation policy.
     
    Bob is also a professor at the University of Denver, in the Law and Society Program, and regularly instructs regarding government regulations, public policy advocacy and various research-based policy courses. He has completed a number of hours toward his PhD at the University of Colorado Graduate School of Public Affairs. He is a regular presenter/lecturer at legal, policy and academic conferences around the country.
    Related Searches
    • ftc
    • fda
    • Regulatory
    • Research
    Related Knowledge Center
    • Dietary Supplements
    • Healthcare Trends
    • Regulations
    Suggested For You
    The Pet Health Boom: Supplement Growth Set to Build on Rapid Expansion The Pet Health Boom: Supplement Growth Set to Build on Rapid Expansion
    Review Finds No Causative Connection Between Dietary Supplements and Eating Disorders Review Finds No Causative Connection Between Dietary Supplements and Eating Disorders
    CBD, Other Cannabinoids Well-Tolerated Among Healthy Dogs: Study Commissioned by NASC CBD, Other Cannabinoids Well-Tolerated Among Healthy Dogs: Study Commissioned by NASC
    CRN Petitions FDA to Change Course on CRN Petitions FDA to Change Course on 'Drug Preclusion'
    Podcast: Steve Mister on Regulatory Concerns, the Drug Exclusion Clause in DSHEA, and FTC Warnings on Health Claims Podcast: Steve Mister on Regulatory Concerns, the Drug Exclusion Clause in DSHEA, and FTC Warnings on Health Claims
    Ingredient Overages Widespread in Melatonin Gummies, Study Claims Ingredient Overages Widespread in Melatonin Gummies, Study Claims
    What the Modernization of Cosmetics Regulation Act Means for Hemp and CBD Cosmetic Manufacturers What the Modernization of Cosmetics Regulation Act Means for Hemp and CBD Cosmetic Manufacturers
    CBD and Pet Health: Wellness for Our Four-Legged Friends CBD and Pet Health: Wellness for Our Four-Legged Friends
    Charlotte’s Web Co-Founder Talks Sleep Tips with CBD Charlotte’s Web Co-Founder Talks Sleep Tips with CBD
    Shaping and Leading an Industry without a Clear Regulatory Framework Shaping and Leading an Industry without a Clear Regulatory Framework
    CBD Innovation and Regulation in Canada: Background, Landscape, and the Future CBD Innovation and Regulation in Canada: Background, Landscape, and the Future
    Sisters of the Valley: Activists on a Mission to Heal the World Sisters of the Valley: Activists on a Mission to Heal the World
    CBD’s Search for Solid Ground  CBD’s Search for Solid Ground
    CBD MarketWatch 2023: FDA Claims New Regulatory Pathway Needed for CBD CBD MarketWatch 2023: FDA Claims New Regulatory Pathway Needed for CBD
    Economic Pressures Lead to Slower Growth in Dietary Supplement Industry Economic Pressures Lead to Slower Growth in Dietary Supplement Industry

    Related Features

    • Consumer Trends | Delivery & Dosage Technologies | Dietary Supplements | Pet Nutraceuticals | Quality & Safety | Regulations | Research | Testing
      The Pet Health Boom: Supplement Growth Set to Build on Rapid Expansion

      The Pet Health Boom: Supplement Growth Set to Build on Rapid Expansion

      The pandemic compelled many people to add a furry friend to their family, and their spending habits demonstrate a dedication to health.
      By Sean Moloughney, Editor 05.30.23

    • Dietary Supplements | Healthcare Trends | Research | Sports Nutrition | Weight Management/Weight Loss
      Review Finds No Causative Connection Between Dietary Supplements and Eating Disorders

      Review Finds No Causative Connection Between Dietary Supplements and Eating Disorders

      Studies attempting to link supplements to ED are inadequately designed, and often conflate drugs and dietary supplements.
      By Mike Montemarano, Associate Editor 05.23.23

    • Breaking News | Industry & Market News | Pet Nutraceuticals | Quality & Safety | Research
      CBD, Other Cannabinoids Well-Tolerated Among Healthy Dogs: Study Commissioned by NASC

      CBD, Other Cannabinoids Well-Tolerated Among Healthy Dogs: Study Commissioned by NASC

      Study with Nutrasource concluded a daily dose of 5 mg total cannabinoids per kg of body weight for 90 consecutive days did not pose significant risk.
      05.17.23


    • Breaking News | Dietary Supplements | Industry & Market News | Regulations | Regulatory News
      CRN Petitions FDA to Change Course on

      CRN Petitions FDA to Change Course on 'Drug Preclusion'

      CRN asked for clearer and more consistent application of the statute which prohibits ingredients from dietary supplements due to past drug research.
      By Mike Montemarano, Associate Editor 05.10.23

    • Dietary Supplements | Healthcare Trends | Herbs & Botanicals | Minerals | Proteins, Peptides, Amino Acids | Quality & Safety | Regulations | Testing | Vitamins
      Podcast: Steve Mister on Regulatory Concerns, the Drug Exclusion Clause in DSHEA, and FTC Warnings on Health Claims

      Podcast: Steve Mister on Regulatory Concerns, the Drug Exclusion Clause in DSHEA, and FTC Warnings on Health Claims

      The Council for Responsible Nutrition's president and CEO also reflected on the association's 50th anniversary, its values, and priorities.
      Sean Moloughney, Editor 04.28.23

    Loading, Please Wait..
    Trending
    • Soviets Took Probiotics To The Next Level
    • Shiitake Mushroom Extract Appears Helpful In HPV Infections
    • Study Examines Vitamin K2 Content In Cheese
    • HMB And Vitamin D Supplementation Linked To Reduction In Fat Stores
    Breaking News
    • Verdure Sciences Receives Award for Sustainable, Ethical Turmeric Sourcing
    • BGG Receives Patent for Saw Palmetto ID Method
    • Premium Label & Packaging Solutions Receives Safe Quality Food (SQF) Certification
    • Inulinase Enzymes May Benefit Gut Symptoms of FODMAP Digestion
    • Verdure Sciences’ Boswellia Ingredient Receives USP Verification
    View Breaking News >
    CURRENT ISSUE

    May 2023

    • Cellular Aging and Longevity: Ingredients for a New Age of Health
    • Addressing the Plastic-Packaging Problem: Getting to Zero-Waste with Zero Compromise
    • Moms Raise the Bar for Kids Supplements
    • Building on Steps to Improve Children’s Health Around the World
    • FDA Remains Focused on Modernizing DSHEA
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Verdure Sciences Receives Award for Sustainable, Ethical Turmeric Sourcing
    BGG Receives Patent for Saw Palmetto ID Method
    Premium Label & Packaging Solutions Receives Safe Quality Food (SQF) Certification
    Coatings World

    Latest Breaking News From Coatings World

    IMCD Strengthens North America Technical Capabilities with New Lab
    Sherwin-Williams Leads Global Paints Brands in Value: Brand Finance
    Arkema Partnering with Habitat for Humanity Philadelphia
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Japanese Regulators Approve EDAP's ExactVu Micro-Ultrasound
    Celanese Forges Agreement With Glaukos for Sustained Release Glaucoma Treatment
    Cardio Diagnostic Holdings, Lifespan.io Collaborate on Heart Disease Research
    Contract Pharma

    Latest Breaking News From Contract Pharma

    FDA Approves Pfizer’s ABRYSVO Vax for RSV Prevention
    Novartis Buys Avrobio Gene Therapy for $88 Million
    Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Selva Ventures Closes $34M Second Fund Backed by Unilever
    Sharon Chuter Steps Down as CEO & Board Member at Uoma Beauty
    Saks Says Consumer Interest in Luxury Remains
    Happi

    Latest Breaking News From Happi

    MAC Cosmetics Launches Day of Giving To Benefit Viva Glam Campaign
    Attitude Cosmetics Enters Makeup Category with Solid Makeup Line in Plastic-Free Packaging
    Credo Picks Up Arey Haircare for Grey Hair
    Ink World

    Latest Breaking News From Ink World

    IMCD Strengthens North America Technical Capabilities
    Arkema Partners with Habitat for Humanity Philadelphia
    HP Inc. Reports Fiscal 2023 Second Quarter Results
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    ACTEGA teams with Makro Labelling to advance Signite technology
    Constantia Flexibles and SB Packagings commence joint venture
    Inland donates new VersaStudio printer to local high school
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Biodiapers Signs Agreement with Sicam
    Sinaatec Uses Two A.Celli End-Of-Line Solutions
    Mann+Hummel Names President Air Filtration Americas
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Artelon Closes $20M Series B Funding
    Orthofix Unveils Seven-Year Outcome Data for M6-C Artificial Cervical Disc
    Enrollment Completed in Anika Therapeutics' Hyalofast Study
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Arkema Collaborates with Habitat for Humanity Philadelphia
    Vitesco Technologies, onsemi Sign SiC Long-Term Supply Agreement
    Ambiq Receives 2023 Bronze Stevie Award

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login